OARD1: A Potential Drug Target for Various Diseases (G221443)

Target Name: OARD1

NCBI ID: G221443

OARD1

OARD1: A Potential Drug Target for Various Diseases

OARD1 (O-acetyl-ADP-ribose deacetylase) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a key enzyme in the degradation pathway of acetyl-ADP-ribose (AAR), which is a key intracellular signaling molecule. In this article, we will discuss OARD1 as a potential drug target and its potential role in the treatment of various diseases.

OARD1 is a 21-kDa protein that is expressed in the brain, heart, and kidneys. It is highly conserved across various species, with a calculated pI of 4.92. OARD1 is a member of the superfamily of NAD+-dependent enzymes, which includes enzymes involved in various cellular processes, including metabolism, stress response, and signaling pathways.

One of the unique features of OARD1 is its catalytic mechanism. It is a type of ATP-dependent enzyme that uses a NAD+ electron acceptor to catalyze the deacetylation of AAR. This reaction is reversible, and the enzyme can also catalyze the addition of an acetyl group to AAR. The NAD+ electron acceptor is located on the active site of the enzyme, and it is involved in the transfer of electrons during the reaction.

OARD1 has been shown to play a role in various cellular processes. For example, OARD1 has been shown to be involved in the regulation of cellular stress response, DNA damage repair, and metabolism. OARD1 has also been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases.

As a potential drug target, OARD1 has been identified as a potential target for several diseases. One of the main reasons for its potential as a drug target is its involvement in various cellular processes that are disrupted in diseases such as cancer, neurodegenerative diseases, and cardiovascular diseases. For example, OARD1 has been shown to be involved in the regulation of cell division, apoptosis, and autophagy, which are all processes that are disrupted in cancer cells.

Another reason for OARD1's potential as a drug target is its role in the development and progression of neurodegenerative diseases. OARD1 has been shown to be involved in the regulation of neurotransmitter synthesis and release, as well as the regulation of pain perception. It has also been shown to play a role in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

In addition to its involvement in neurodegenerative diseases, OARD1 has also been shown to be involved in the regulation of cardiovascular disease. OARD1 has been shown to play a role in the regulation of blood pressure, angiotensin-converting enzyme (ACE) activity, and inflammation. It has also been shown to be involved in the development and progression of cardiovascular disease, including myocardial infarction and stroke.

In conclusion, OARD1 is a protein that has been shown to play a role in various cellular processes that are involved in the development and progression of diseases. As a potential drug target, OARD1 has the potential to be used to treat a variety of diseases, including cancer, neurodegenerative diseases, and cardiovascular disease. Further research is needed to fully understand the role of OARD1 in disease and to develop effective treatments.

Protein Name: O-acyl-ADP-ribose Deacylase 1

Functions: ADP-ribose glycohydrolase that hydrolyzes ADP-ribose and acts on different substrates, such as proteins ADP-ribosylated on glutamate and O-acetyl-ADP-D-ribose (PubMed:23481255, PubMed:23474714, PubMed:21849506). Specifically acts as a glutamate mono-ADP-ribosylhydrolase by mediating the removal of mono-ADP-ribose attached to glutamate residues on proteins (PubMed:23481255, PubMed:23474714). Does not act on poly-ADP-ribosylated proteins: the poly-ADP-ribose chain of poly-ADP-ribosylated glutamate residues must by hydrolyzed into mono-ADP-ribosylated glutamate by PARG to become a substrate for OARD1 (PubMed:23481255). Deacetylates O-acetyl-ADP ribose, a signaling molecule generated by the deacetylation of acetylated lysine residues in histones and other proteins (PubMed:21849506). Catalyzes the deacylation of O-acetyl-ADP-ribose, O-propionyl-ADP-ribose and O-butyryl-ADP-ribose, yielding ADP-ribose plus acetate, propionate and butyrate, respectively (PubMed:21849506)

The "OARD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OARD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets